Literature DB >> 17143556

Phytocomponent p-hydroxycinnamic acid inhibits osteoclast-like cell formation in mouse bone marrow cultures.

Ying Ling Lai1, Masayoshi Yamaguchi.   

Abstract

The phytocomponent p-hydroxycinnamic acid (HCA) has been shown to have inhibitory effects on bone-resorbing factor-stimulated bone resorption in rat femoral tissues in vitro. The effects of HCA on osteoclast-like cell formation in mouse bone marrow cultures in vitro were investigated. The bone marrow cells were cultured for 7 days in alpha-minimal essential medium containing a bone-resorbing agent [parathyroid hormone (1-34)] (PTH), prostaglandin E2 (PGE2), or tumor necrosis factor-alpha (TNF-alpha) in effective concentrations. Osteoclast-like cell formation was estimated by staining for tartrate-resistant acid phosphatase, a marker enzyme of osteoclasts. The presence of PTH (10(-7) M), PGE2 (10(-5) M), or TNF-alpha (10 ng/ml) induced a remarkable increase in osteoclast-like multinucleated cells. These increases were significantly inhibited in the presence of HCA (10(-8)-10(-5) M). HCA (10(-6) or 10(-5) M) significantly inhibited osteoclast-like cell formation induced by dibutyryl cyclic adenosine monophosphate (10(-5) M) or phorbol 12-myristate 13-acetate (10(-6) M), an activator of protein kinase C. Also, HCA (10(-8)-10(-5) M) had a significant inhibitory effect on osteoclast-like cell formation induced by the receptor activator of NF-kappaB ligand (RANKL) (10 ng/ml) in the presence of macrophage colony-stimulating factor (M-CSF) (10 ng/ml). The inhibitory effect of HCA (10(-6) or 10(-5) M) on RANKL plus M-CSF-induced osteoclast-like cell formation was not observed in the presence of cycloheximide (10(-7) M), an inhibitor of protein synthesis in the transcriptional process, or 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (10(-6) M), an inhibitor of transcription. This study demonstrates that HCA has a potent inhibitory effect on osteoclast-like cell formation in mouse bone marrow cultures. The inhibitory action of HCA may partly involve a newly synthesized protein component which is related to RANKL stimulation in osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17143556

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  7 in total

1.  Oral administration of phytocomponent p-hydroxycinnamic acid prevents bone loss in ovariectomized rats.

Authors:  Masayoshi Yamaguchi; Ying Ling Lai; Satoshi Uchiyama; Taeko Nakagawa
Journal:  Mol Cell Biochem       Date:  2007-12-30       Impact factor: 3.396

Review 2.  The botanical molecule p-hydroxycinnamic acid as a new osteogenic agent: insight into the treatment of cancer bone metastases.

Authors:  Masayoshi Yamaguchi
Journal:  Mol Cell Biochem       Date:  2016-08-30       Impact factor: 3.396

3.  The botanical component p-hydroxycinnamic acid suppresses the growth and bone metastatic activity of human prostate cancer PC-3 cells in vitro.

Authors:  Masayoshi Yamaguchi; Tomiyasu Murata; Joe W Ramos
Journal:  J Cancer Res Clin Oncol       Date:  2020-10-01       Impact factor: 4.553

4.  The phytochemical p-hydroxycinnamic acid suppresses the growth and stimulates the death in human liver cancer HepG2 cells.

Authors:  Masayoshi Yamaguchi; Tomiyasu Murata; Joe W Ramos
Journal:  Anticancer Drugs       Date:  2021-06-01       Impact factor: 2.389

5.  Bioactive flavonoid p-hydroxycinnamic acid stimulates osteoblastogenesis and suppresses adipogenesis in bone marrow culture.

Authors:  Masayoshi Yamaguchi; Clifton A Baile; Shijun Zhu; Mamoru Shoji
Journal:  Cell Tissue Res       Date:  2013-09-13       Impact factor: 5.249

Review 6.  Molecular signaling mechanisms behind polyphenol-induced bone anabolism.

Authors:  Elisa Torre
Journal:  Phytochem Rev       Date:  2017-08-31       Impact factor: 5.374

7.  Phenolic Compounds in Extra Virgin Olive Oil Stimulate Human Osteoblastic Cell Proliferation.

Authors:  Olga García-Martínez; Elvira De Luna-Bertos; Javier Ramos-Torrecillas; Concepción Ruiz; Egle Milia; María Luisa Lorenzo; Brigida Jimenez; Araceli Sánchez-Ortiz; Ana Rivas
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.